The 9th China International Import Expo (CIIE) took place in Shanghai from November5to10, 2026. This year's expo reached a new scale: 162 countries, regions and international organizations participated; 4,142 overseas companies exhibited; the enterprise exhibition area topped 370,000 square meters for the first time; more than 300 Fortune Global 500 and industry-leading companies took part; and more than 480 representative debut products were showcased. At this open platform, VIKPRO, a high-end German dietary nutrition brand, exhibited for the sixth time, showcasing its quality practices and innovations in coenzyme Q10 under the theme “German Technology · Cellular Nutrition.”
Deepening the Coenzyme Q10 Track: Strengthening Quality Through Market Certification and Third-Party Verification
VIKPRO upholds the brand core of “science, rigor and quality” and has built deep expertise in coenzyme Q10. In May 2026, Euromonitor International certified VIKPRO as “the leading European brand in online sales of reduced coenzyme Q10 (ubiquinol) for two consecutive years.” The certification is based on independent market monitoring and audits of consecutive annual sales data, reflecting the brand's market performance in the ubiquinol coenzyme Q10 segment.
At this year's CIIE, Kaneka presented VIKPRO with a verification certificate for its reduced coenzyme Q10. VIKPRO' ubiquinol coenzyme Q10 has passed verification under the Ubiquinol Verified Program, jointly run by Kaneka and Eurofins. Independent testing by Eurofins confirmed that the classic ubiquinol coenzyme Q10 product contains Kaneka Ubiquinol at the declared content, and the verification results are publicly searchable. Kaneka has more than 45 years of Ubiquinol research experience; Eurofins operates 950 laboratories in more than 60 countries and provides independent analytical testing services. The verification gives consumers a public, verifiable basis for identifying authentic ubiquinol products. It also reflects VIKPRO's commitment to quality transparency and supports the transparent, healthy development of the supplement industry.
Joint First Launch With JD Health: Dual-Chamber Heart Vitality Drink Advances Dosage-Form Innovation
On November 6, VIKPRO and JD Health jointly launched the world's first phospholipid-based ubiquinol dual-chamber Heart Vitality Drink, further advancing dosage-form innovation in coenzyme Q10. Developed for professionals under high workplace pressure, the product provides nutritional support for cardiac, cognitive and physical energy demands under intense work schedules.
According to the company, the product uses MPL+® cell-level phospholipid delivery technology, jointly developed by VIKPRO and the University of Düsseldorf, and achieves 14-fold bioavailability. Its dosage form separates reduced coenzyme Q10 powder and liquid into two chambers—a fresh-lock chamber and a liquid chamber—stored separately and ready to drink upon opening, helping preserve nutrient activity. The formula centers on Kaneka ubiquinol coenzyme Q10 and combines ginsenoside Rg1, six B vitamins and creatine into a nine-nutrient blend.
Having exhibited at CIIE six times, VIKPRO has demonstrated a complete quality chain—from market performance to third-party verification to dosage-form innovation. Competition in the dietary nutrition industry is shifting from comparisons of single ingredients to a systemic contest over absorption efficiency and quality credibility. With verifiable data, traceable testing and a perceivable dosage-form experience, VIKPRO continues to reinforce its “German standards” quality narrative and offers the industry a transparent benchmark. In the future, VIKPRO will continue to use the CIIE open platform to deepen its presence in the Chinese market and, through high-standard quality practices, contribute to the transparent and healthy development of the supplement industry.
